aminoglutethimide has been researched along with Bone Cancer in 47 studies
Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.
aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this prospective, randomized study the clinical response and toxicity of megestrol acetate (MA) and aminoglutethimide (AG) as second-line treatment in patients with metastatic breast cancer was compared." | 9.06 | Megestrol acetate versus aminoglutethimide for metastatic breast cancer. ( Gundersen, S; Klepp, R; Kvinnsland, S; Lund, E; Lundgren, S; Lønning, PE, 1989) |
| "The therapeutic efficacy of combined endocrine therapy with tamoxifen, aminoglutethimide and hydrocortisone (T+AG+H) was evaluated against treatment with tamoxifen (T) alone in 210 patients above 65 years of age with metastatic breast cancer." | 9.06 | Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone. ( Andersen, AP; Andersen, KW; Bastholt, L; Brincker, H; Dombernowsky, P; Kamby, C; Loft, H; Mouridsen, HT; Rose, C; Skovgaard-Poulsen, H, 1986) |
| "54 patients (pts) with metastatic breast cancer were treated with aminoglutethimide 250 mg p." | 7.69 | [Use of aminoglutethimide in the hormonal treatment of patients with advanced breast cancer]. ( Czech, I; Dziewulska-Bokiniec, A; Wojtacki, J, 1994) |
| "The aim of this study is to report on Aminoglutethimide-induced hormonal modifications in advanced breast cancer." | 7.67 | Preliminary study of hormone determinations during aminoglutethimide therapy for advanced breast cancer. ( Díaz, L; Koliren, L; Loruso, A; Ramos, G; Scaglia, HE; Soto, E; Zylbersztein, C, 1984) |
| "Aminoglutethimide (AG) was administered as palliative therapy in 112 patients with metastatic breast cancer." | 7.67 | Aminoglutethimide in patients with metastatic breast cancer. ( Dao, TL; Nemoto, T; Patel, JK; Rosner, D, 1989) |
| "One hundred twenty-eight women with advanced metastatic breast cancer were treated with a combination of aminoglutethimide (AG) (1000 mg orally, daily) and medroxyprogesterone acetate (MPA) (1500 mg orally, daily for six weeks and thereafter 500 mg orally, daily; omitting cortisone substitution)." | 7.67 | Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO). ( Blossey, HC; Kleeberg, U; Nagel, GA; Wander, HE, 1986) |
| "Seventy-two women with advanced breast cancer were treated with aminoglutethimide and hydrocortisone (AG)." | 7.67 | Aminoglutethimide as second line therapy in advanced breast cancer. ( Blomqvist, C; Elomaa, I; Rissanen, P, 1986) |
| "In a phase II study, 38 evaluable patients with advanced progressive breast cancer were treated with 4 X 250 mg of aminoglutethimide per day without hydrocortisone supplementation." | 7.67 | Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer. ( Faber, P; Höffken, K; Kempf, H; Kley, HK; Miller, AA; Miller, B; Schmidt, CG, 1986) |
| "A clinical phase II study was performed to evaluate the therapeutic efficacy of simultaneously administered aminoglutethimide and polychemotherapy in 31 patients with predominant bone metastases of breast cancer." | 7.67 | [Combination of aminoglutethimide and polychemotherapy for the treatment of predominant bone metastasis in breast cancer]. ( Dabag, S; Rieche, K; Scharlau, L, 1986) |
| "Sixty-five patients with advanced breast cancer, progressive despite prior endocrine therapy in all cases and prior chemotherapy in most cases, were treated with aminoglutethimide, 250 mg four times a day." | 7.66 | Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer. ( Coates, AS; Fox, RM; Kaye, SB; Tattersall, MH; Woods, RL, 1982) |
| "Aminoglutethimide (AG) with Dexamethasone has been utilized in 26 patients with metastatic breast cancer who had prior response to hormonal manipulation and/or positive estrogen receptor." | 7.66 | Aminoglutethimide in the management of metastatic breast cancer. ( Savaraj, N; Troner, MB, 1980) |
| "Oestrogen receptor (ER) measurements in metastatic and primary tumours from patients with breast cancer have been correlated with the objective tumour response to treatment with aminoglutethimide (24 patients) or tamoxifen (39 patients)." | 7.66 | Oestrogen receptors and the response of metastatic breast cancer to aminoglutethimide or tamoxifen. ( Holdaway, IM, 1981) |
| "Aminoglutethimide in combination with dexamethasone has been used in 44 patients with metastatic breast cancer who had prior response to hormonal manipulation and/or positive estrogen receptors." | 7.66 | Aminoglutethimide in the treatment of metastatic breast cancer. ( Troner, MB, 1982) |
| "A group of 213 unselected postmenopausal women with advanced breast cancer were treated with aminoglutethimide, 250 mg 4 times a day, and hydrocortisone, 20 mg 2 times a day." | 7.66 | Aminoglutethimide in the treatment of advanced postmenopausal breast cancer. ( Harris, AL; Powles, TJ; Smith, IE, 1982) |
| "A 54-year-old woman had a primary breast cancer with an estrogen receptor of 11." | 5.27 | Response to aminoglutethimide after failure of tamoxifen therapy in breast cancer. ( Carter, RD; Muchmore, JH; Sutherland, CM, 1985) |
| "In this prospective, randomized study the clinical response and toxicity of megestrol acetate (MA) and aminoglutethimide (AG) as second-line treatment in patients with metastatic breast cancer was compared." | 5.06 | Megestrol acetate versus aminoglutethimide for metastatic breast cancer. ( Gundersen, S; Klepp, R; Kvinnsland, S; Lund, E; Lundgren, S; Lønning, PE, 1989) |
| "The therapeutic efficacy of combined endocrine therapy with tamoxifen, aminoglutethimide and hydrocortisone (T+AG+H) was evaluated against treatment with tamoxifen (T) alone in 210 patients above 65 years of age with metastatic breast cancer." | 5.06 | Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone. ( Andersen, AP; Andersen, KW; Bastholt, L; Brincker, H; Dombernowsky, P; Kamby, C; Loft, H; Mouridsen, HT; Rose, C; Skovgaard-Poulsen, H, 1986) |
| "Altogether 117 patients with advanced breast cancer were treated with either tamoxifen 10 mg by mouth twice daily or aminoglutethimide 250 mg by mouth four times daily with hydrocortisone 20 mg twice daily in a randomised cross-over trial in which patients who failed to respond to the first treatment or relapsed while receiving it were switched to the other." | 5.05 | Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. ( Ford, HT; Gazet, JC; Harmer, CL; Harris, AL; McKinna, JA; Morgan, M; Parsons, CA; Smith, IE; Villardo, A; Walsh, G; White, H, 1981) |
| "Hormonotherapy in metastatic breast cancer is actually performed using 3 therapeutic classes: antiestrogen as tamoxifen (TAM), progestins, megestrol acetate (MA) and medroxyprogesterone acetate (MPA), aromatase-inhibitors as aminoglutethimide (AG)." | 4.79 | [Progestational agents and bone metastasis in breast cancer]. ( Bonneterre, J; Leriche, N, 1997) |
| "54 patients (pts) with metastatic breast cancer were treated with aminoglutethimide 250 mg p." | 3.69 | [Use of aminoglutethimide in the hormonal treatment of patients with advanced breast cancer]. ( Czech, I; Dziewulska-Bokiniec, A; Wojtacki, J, 1994) |
| "We report a case of radiotherapy-enhanced aminoglutethimide skin toxicity in a patient with metastatic breast cancer." | 3.68 | Radiotherapy enhances the toxicity of aminoglutethimide. ( Buzdar, AU; Hortobagyi, GN; Vanek, N, 1990) |
| "The aim of this study is to report on Aminoglutethimide-induced hormonal modifications in advanced breast cancer." | 3.67 | Preliminary study of hormone determinations during aminoglutethimide therapy for advanced breast cancer. ( Díaz, L; Koliren, L; Loruso, A; Ramos, G; Scaglia, HE; Soto, E; Zylbersztein, C, 1984) |
| "Aminoglutethimide inhibits the synthesis of oestrogens in adrenal and non-adrenal tissues and can be successfully used in the treatment of advanced breast cancer." | 3.67 | [Panmyelopathy induced by aminoglutethimide. Report of a clinical case]. ( Wander, HE, 1984) |
| "Aminoglutethimide (AG) was administered as palliative therapy in 112 patients with metastatic breast cancer." | 3.67 | Aminoglutethimide in patients with metastatic breast cancer. ( Dao, TL; Nemoto, T; Patel, JK; Rosner, D, 1989) |
| "One hundred twenty-eight women with advanced metastatic breast cancer were treated with a combination of aminoglutethimide (AG) (1000 mg orally, daily) and medroxyprogesterone acetate (MPA) (1500 mg orally, daily for six weeks and thereafter 500 mg orally, daily; omitting cortisone substitution)." | 3.67 | Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO). ( Blossey, HC; Kleeberg, U; Nagel, GA; Wander, HE, 1986) |
| "Seventy-two women with advanced breast cancer were treated with aminoglutethimide and hydrocortisone (AG)." | 3.67 | Aminoglutethimide as second line therapy in advanced breast cancer. ( Blomqvist, C; Elomaa, I; Rissanen, P, 1986) |
| "In a phase II study, 38 evaluable patients with advanced progressive breast cancer were treated with 4 X 250 mg of aminoglutethimide per day without hydrocortisone supplementation." | 3.67 | Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer. ( Faber, P; Höffken, K; Kempf, H; Kley, HK; Miller, AA; Miller, B; Schmidt, CG, 1986) |
| "A clinical phase II study was performed to evaluate the therapeutic efficacy of simultaneously administered aminoglutethimide and polychemotherapy in 31 patients with predominant bone metastases of breast cancer." | 3.67 | [Combination of aminoglutethimide and polychemotherapy for the treatment of predominant bone metastasis in breast cancer]. ( Dabag, S; Rieche, K; Scharlau, L, 1986) |
| "Aminoglutethimide in combination with dexamethasone has been used in 44 patients with metastatic breast cancer who had prior response to hormonal manipulation and/or positive estrogen receptors." | 3.66 | Aminoglutethimide in the treatment of metastatic breast cancer. ( Troner, MB, 1982) |
| "A group of 213 unselected postmenopausal women with advanced breast cancer were treated with aminoglutethimide, 250 mg 4 times a day, and hydrocortisone, 20 mg 2 times a day." | 3.66 | Aminoglutethimide in the treatment of advanced postmenopausal breast cancer. ( Harris, AL; Powles, TJ; Smith, IE, 1982) |
| "Aminoglutethimide (AG) with Dexamethasone has been utilized in 26 patients with metastatic breast cancer who had prior response to hormonal manipulation and/or positive estrogen receptor." | 3.66 | Aminoglutethimide in the management of metastatic breast cancer. ( Savaraj, N; Troner, MB, 1980) |
| "Sixty-five patients with advanced breast cancer, progressive despite prior endocrine therapy in all cases and prior chemotherapy in most cases, were treated with aminoglutethimide, 250 mg four times a day." | 3.66 | Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer. ( Coates, AS; Fox, RM; Kaye, SB; Tattersall, MH; Woods, RL, 1982) |
| "Seventy-one patients with breast cancer and bone metastases, together with other assessable sites of disease, were monitored by radiologic skeletal survey, bone scanning, pain charts, bone marrow aspirate, serum calcium, alkaline phosphatase and urine hydroxyproline/creatinine ratio." | 3.66 | Assessment of response of bone metastases to systemic treatment in patients with breast cancer. ( Coombes, RC; Dady, P; Ford, HT; Gazet, JC; McCready, VR; Parsons, C; Powles, TJ, 1983) |
| "Oestrogen receptor (ER) measurements in metastatic and primary tumours from patients with breast cancer have been correlated with the objective tumour response to treatment with aminoglutethimide (24 patients) or tamoxifen (39 patients)." | 3.66 | Oestrogen receptors and the response of metastatic breast cancer to aminoglutethimide or tamoxifen. ( Holdaway, IM, 1981) |
| "A total of 59 patients with advanced prostate cancer relapsed from or refractory to castration plus oestrogen were treated in a randomised trial comparing 1000 to 1250 mg aminoglutethimide + 40 mg hydrocortisone (AG + HC) with 500 mg medroxyprogesterone acetate + 40 mg hydrocortisone (MPA + HC)." | 2.67 | Treatment of stage D2 prostatic cancer refractory to or relapsed following castration plus oestrogens. Comparison of aminoglutethimide plus hydrocortisone with medroxyprogesterone acetate plus hydrocortisone. ( Bezwoda, WR, 1990) |
| "Aminoglutethimide (Elipten), at a dosage between 250 and 1500 mg/d by mouth, was administered in a clinical phase II study to 17 patients with metastasizing carcinoma of the breast resistant to hormones and cytostatic drugs." | 2.65 | [Aminoglutethimide in metastasizing carcinoma of the breast resistant to hormonal and cytostatic treatment (author's transl)]. ( Rieche, K, 1981) |
| " Drug intervention should be on a regular schedule--avoid prn dosage of pain medications." | 1.27 | Dilemmas in managing prostate carcinoma (Part II): Metastatic disease. ( Ahmann, FR, 1985) |
| "A 54-year-old woman had a primary breast cancer with an estrogen receptor of 11." | 1.27 | Response to aminoglutethimide after failure of tamoxifen therapy in breast cancer. ( Carter, RD; Muchmore, JH; Sutherland, CM, 1985) |
| "42 patients with metastatic breast carcinoma were treated with aminoglutethimide, which inhibits adrenal steroid hormone synthesis." | 1.26 | Aminoglutethimide in treatment of metastatic breast carcinoma. ( Fahmy, DR; Fitzharris, BM; Ford, HT; Gazet, JC; McKinna, JA; Nash, AG; Neville, AM; Powles, TJ; Smith, IE, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (78.72) | 18.7374 |
| 1990's | 8 (17.02) | 18.2507 |
| 2000's | 2 (4.26) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mustacchi, G | 1 |
| Muggia, M | 1 |
| Milani, S | 1 |
| Ceccherini, R | 1 |
| Leita, ML | 1 |
| Dellach, C | 1 |
| Hobdy, EM | 1 |
| Shafi, NQ | 1 |
| Kummar, S | 1 |
| Kaye, SB | 1 |
| Woods, RL | 1 |
| Fox, RM | 1 |
| Coates, AS | 1 |
| Tattersall, MH | 1 |
| Coltart, RS | 1 |
| Scaglia, HE | 1 |
| Koliren, L | 1 |
| Loruso, A | 1 |
| Zylbersztein, C | 1 |
| Ramos, G | 1 |
| Díaz, L | 1 |
| Soto, E | 1 |
| Beccati, MD | 1 |
| Degli Azzi Vitelleschi, I | 1 |
| Marangolo, M | 1 |
| Wander, HE | 2 |
| Soloway, MS | 1 |
| Smith, IE | 6 |
| Harris, AL | 3 |
| Morgan, M | 1 |
| Ford, HT | 4 |
| Gazet, JC | 4 |
| Harmer, CL | 1 |
| White, H | 1 |
| Parsons, CA | 1 |
| Villardo, A | 1 |
| Walsh, G | 1 |
| McKinna, JA | 3 |
| Worgul, TJ | 1 |
| Santen, RJ | 3 |
| Samojlik, E | 1 |
| Veldhuis, JD | 1 |
| Lipton, A | 3 |
| Harvey, HA | 2 |
| Drago, JR | 1 |
| Rohner, TJ | 1 |
| Coombes, RC | 2 |
| Dady, P | 1 |
| Parsons, C | 1 |
| McCready, VR | 1 |
| Powles, TJ | 4 |
| Holdaway, IM | 1 |
| Boucher, A | 1 |
| White, D | 1 |
| Bernath, A | 1 |
| Dixon, R | 1 |
| Richards, G | 1 |
| Shafik, A | 1 |
| Troner, MB | 2 |
| Rieche, K | 2 |
| Harmer, C | 1 |
| Jones, M | 1 |
| Savaraj, N | 1 |
| Barry, WF | 1 |
| Wells, SA | 2 |
| Cox, CE | 1 |
| Haagensen, DE | 2 |
| Wojtacki, J | 1 |
| Dziewulska-Bokiniec, A | 1 |
| Czech, I | 1 |
| Bonneterre, J | 2 |
| Adenis, A | 1 |
| Pion, JM | 1 |
| Cambier, L | 1 |
| Kamus, E | 1 |
| Hecquet, B | 1 |
| Leriche, N | 1 |
| Fitzharris, BM | 1 |
| Fahmy, DR | 1 |
| Nash, AG | 1 |
| Neville, AM | 1 |
| Ruby, EJ | 1 |
| Harvey, H | 1 |
| Dilley, WG | 1 |
| Clavel, M | 1 |
| Adshead, F | 1 |
| De Graeff, A | 1 |
| Mansi, JL | 1 |
| Thomas, DM | 1 |
| Bezwoda, WR | 1 |
| Vanek, N | 1 |
| Hortobagyi, GN | 1 |
| Buzdar, AU | 1 |
| Labrie, F | 1 |
| Dupont, A | 1 |
| Bélanger, A | 1 |
| Lacourcière, Y | 1 |
| Béland, L | 1 |
| Cusan, L | 1 |
| Lachance, R | 1 |
| Nemoto, T | 1 |
| Rosner, D | 1 |
| Patel, JK | 1 |
| Dao, TL | 1 |
| Lundgren, S | 1 |
| Gundersen, S | 1 |
| Klepp, R | 1 |
| Lønning, PE | 1 |
| Lund, E | 1 |
| Kvinnsland, S | 1 |
| Tel, W | 1 |
| van Lijf, JH | 1 |
| ten Napel, CH | 1 |
| Nagel, GA | 1 |
| Blossey, HC | 1 |
| Kleeberg, U | 1 |
| Williams, DS | 1 |
| Leslie, MD | 1 |
| Elomaa, I | 2 |
| Blomqvist, C | 2 |
| Rissanen, P | 2 |
| Pieńkowski, T | 1 |
| Zborzil, J | 1 |
| Siedlecki, P | 1 |
| Flis, E | 1 |
| Pałucka, A | 1 |
| Pieńkowska, F | 1 |
| Rubách, M | 1 |
| Piotrowski, J | 1 |
| Huang, HY | 1 |
| Fei, LM | 1 |
| Liu, WH | 1 |
| Taube, T | 1 |
| Rannikko, S | 1 |
| Alfthan, O | 1 |
| Rose, C | 1 |
| Kamby, C | 1 |
| Mouridsen, HT | 1 |
| Bastholt, L | 1 |
| Brincker, H | 1 |
| Skovgaard-Poulsen, H | 1 |
| Andersen, AP | 1 |
| Loft, H | 1 |
| Dombernowsky, P | 1 |
| Andersen, KW | 1 |
| Höffken, K | 1 |
| Kempf, H | 1 |
| Miller, AA | 1 |
| Miller, B | 1 |
| Schmidt, CG | 1 |
| Faber, P | 1 |
| Kley, HK | 1 |
| Dabag, S | 1 |
| Scharlau, L | 1 |
| Ahmann, FR | 1 |
| Sutherland, CM | 1 |
| Muchmore, JH | 1 |
| Carter, RD | 1 |
| Macaulay, V | 1 |
| Robinson, MR | 1 |
| Shearer, RJ | 1 |
| Fergusson, JD | 1 |
| Griffiths, CT | 1 |
| Hall, TC | 1 |
| Saba, Z | 1 |
| Barlow, JJ | 1 |
| Nevinny, HB | 1 |
4 reviews available for aminoglutethimide and Bone Cancer
| Article | Year |
|---|---|
[Progestational agents and bone metastasis in breast cancer].
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Dose-Response | 1997 |
Management of breast cancer with bone metastases.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; | 1991 |
[Advanced breast cancer treated with aminoglutethimide].
Topics: Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Humans | 1986 |
Could aminoglutethimide replace adrenalectomy?
Topics: Adrenal Cortex; Adrenalectomy; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Clinical Trials | 1985 |
9 trials available for aminoglutethimide and Bone Cancer
| Article | Year |
|---|---|
A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone | 2002 |
Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Res | 1981 |
Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
Topics: Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Castration; Clinical Trials as Topic; Drug Admi | 1982 |
[Aminoglutethimide in metastasizing carcinoma of the breast resistant to hormonal and cytostatic treatment (author's transl)].
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Humans; Middle Aged; Nause | 1981 |
Treatment of stage D2 prostatic cancer refractory to or relapsed following castration plus oestrogens. Comparison of aminoglutethimide plus hydrocortisone with medroxyprogesterone acetate plus hydrocortisone.
Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Mo | 1990 |
Megestrol acetate versus aminoglutethimide for metastatic breast cancer.
Topics: Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Follow-Up Studies; Humans; Megest | 1989 |
[Early results of hormonal treatment of advanced breast cancer with aminoglutethimide].
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Tr | 1988 |
Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.
Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neop | 1986 |
Could aminoglutethimide replace adrenalectomy?
Topics: Adrenal Cortex; Adrenalectomy; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Clinical Trials | 1985 |
35 other studies available for aminoglutethimide and Bone Cancer
| Article | Year |
|---|---|
Prostate cancer metastasis to supraclavicular lymph node.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Prot | 2004 |
Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Humans; Middle Aged; Nause | 1982 |
Severe mucocutaneous reaction to aminoglutethamide.
Topics: Aged; Aminoglutethimide; Bone Neoplasms; Drug Eruptions; Female; Humans; Middle Aged; Mouth Diseases | 1984 |
Preliminary study of hormone determinations during aminoglutethimide therapy for advanced breast cancer.
Topics: Adult; Aged; Aldosterone; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Dehydroepiandrosteron | 1984 |
[Pharmacological suppression of the adrenal gland. Considerations on a clinical case].
Topics: Adenocarcinoma, Mucinous; Adrenocortical Hyperfunction; Adult; Aminoglutethimide; Antineoplastic Age | 1982 |
[Panmyelopathy induced by aminoglutethimide. Report of a clinical case].
Topics: Aminoglutethimide; Bone Marrow Diseases; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy | 1984 |
Newer methods of hormonal therapy for prostate cancer.
Topics: Adenocarcinoma; Aminoglutethimide; Androgen Antagonists; Bone Neoplasms; Buserelin; Flutamide; Gonad | 1984 |
Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Aminoglutethimide; Bone Neoplasms; Dihydrotestosterone; Drug Therapy, Combinat | 1983 |
Assessment of response of bone metastases to systemic treatment in patients with breast cancer.
Topics: Alkaline Phosphatase; Aminoglutethimide; Antineoplastic Agents; Bone Marrow; Bone Neoplasms; Breast | 1983 |
Oestrogen receptors and the response of metastatic breast cancer to aminoglutethimide or tamoxifen.
Topics: Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Humans; Receptors, Estrogen; Skin Neopl | 1981 |
Aminoglutethimide in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Dexamethasone; Drug Therapy, Combi | 1982 |
Aminoglutethimide in the treatment of advanced postmenopausal breast cancer.
Topics: Age Factors; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Drug Evaluation; Drug Therapy, Com | 1982 |
Aminoglutethimide in the management of advanced breast cancer.
Topics: Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Humans; Liver Neoplasms; Lung Neo | 1980 |
Aminoglutethimide in the management of metastatic breast cancer.
Topics: Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Dexamethasone; Drug Therapy, Combination; | 1980 |
Clinical and radiographic correlations in breast cancer patients with osseous metastases.
Topics: Adrenalectomy; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Humans; Middle Age | 1981 |
[Use of aminoglutethimide in the hormonal treatment of patients with advanced breast cancer].
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; | 1994 |
Aminoglutethimide (AG) and hydrocortisone (HC) in bone metastases: a retrospective study.
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Follow-Up Studies; Humans; | 1993 |
Aminoglutethimide in treatment of metastatic breast carcinoma.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neopl | 1978 |
Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma.
Topics: Adrenal Cortex; Adrenalectomy; Aldosterone; Aminoglutethimide; Androstenedione; Bone Neoplasms; Brea | 1978 |
Small cell carcinoma of the prostate: implications for management.
Topics: Adenocarcinoma; Aminoglutethimide; Bone Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Doxorubi | 1991 |
Radiotherapy enhances the toxicity of aminoglutethimide.
Topics: Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Drug E | 1990 |
Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report.
Topics: Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neop | 1990 |
Aminoglutethimide in patients with metastatic breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Drug Administration Schedule; Fema | 1989 |
[Transient bone marrow inhibition caused by aminoglutethimide].
Topics: Adenocarcinoma; Aminoglutethimide; Bone Marrow Diseases; Bone Neoplasms; Breast Neoplasms; Female; H | 1989 |
Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO).
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brea | 1986 |
Skin reaction following aminoglutethimide and radiotherapy.
Topics: Aminoglutethimide; Bone Neoplasms; Combined Modality Therapy; Drug Eruptions; Erythema; Female; Huma | 1987 |
Aminoglutethimide as second line therapy in advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brea | 1986 |
Aminoglutethimide for advanced prostatic cancer resistant to conventional hormonal therapy.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Bone Neoplasms; Drug Therapy, Combination; Humans; Hydro | 1988 |
Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Drug Evaluation; Female; Hormones; | 1986 |
[Combination of aminoglutethimide and polychemotherapy for the treatment of predominant bone metastasis in breast cancer].
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; | 1986 |
Dilemmas in managing prostate carcinoma (Part II): Metastatic disease.
Topics: Aged; Aminoglutethimide; Aspirin; Bone Neoplasms; Castration; Diethylstilbestrol; Disseminated Intra | 1985 |
Response to aminoglutethimide after failure of tamoxifen therapy in breast cancer.
Topics: Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Middle Ag | 1985 |
Comparison of different endocrine therapies in management of bone metastases from breast carcinoma.
Topics: Adrenal Cortex Hormones; Adrenalectomy; Aminoglutethimide; Androgens; Bone Neoplasms; Breast Neoplas | 1985 |
Adrenal suppression in the treatment of carcinoma of the prostate.
Topics: Acid Phosphatase; Administration, Oral; Adrenal Glands; Aged; Alkaline Phosphatase; Aminoglutethimid | 1974 |
Preliminary trial of aminoglutethimide in breast cancer.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Administration, Oral; Aminoglutethimide; Antineoplastic | 1973 |